ZA202409975B - Methods of treating schizophrenia - Google Patents

Methods of treating schizophrenia

Info

Publication number
ZA202409975B
ZA202409975B ZA2024/09975A ZA202409975A ZA202409975B ZA 202409975 B ZA202409975 B ZA 202409975B ZA 2024/09975 A ZA2024/09975 A ZA 2024/09975A ZA 202409975 A ZA202409975 A ZA 202409975A ZA 202409975 B ZA202409975 B ZA 202409975B
Authority
ZA
South Africa
Prior art keywords
methods
schizophrenia
treatment
determining
treating schizophrenia
Prior art date
Application number
ZA2024/09975A
Other languages
English (en)
Inventor
Seth Hopkins
Kenneth Koblan
Antony Loebel
Ajay Ogirala
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of ZA202409975B publication Critical patent/ZA202409975B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
ZA2024/09975A 2017-02-16 2024-12-23 Methods of treating schizophrenia ZA202409975B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762459784P 2017-02-16 2017-02-16

Publications (1)

Publication Number Publication Date
ZA202409975B true ZA202409975B (en) 2025-09-25

Family

ID=61692045

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/09975A ZA202409975B (en) 2017-02-16 2024-12-23 Methods of treating schizophrenia

Country Status (11)

Country Link
US (3) US11129807B2 (enExample)
EP (1) EP3582815A1 (enExample)
JP (2) JP7146782B2 (enExample)
KR (1) KR102605854B1 (enExample)
CN (2) CN116808023A (enExample)
AU (2) AU2018220509B2 (enExample)
CA (1) CA3053903A1 (enExample)
IL (2) IL268694B2 (enExample)
MX (2) MX390141B (enExample)
WO (1) WO2018151861A1 (enExample)
ZA (1) ZA202409975B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201401661RA (en) 2009-12-04 2014-07-30 Sunovion Pharmaceuticals Inc Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders
CN110087687A (zh) 2016-07-29 2019-08-02 赛诺维信制药公司 化合物、组合物及其用途
JP7146782B2 (ja) 2017-02-16 2022-10-04 サノビオン ファーマシューティカルズ インク 統合失調症を処置する方法
CN111183138A (zh) 2017-08-02 2020-05-19 赛诺维信制药公司 异色满化合物以及用途
WO2019161236A1 (en) * 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Methods of treating social function disorders
KR102746817B1 (ko) 2018-02-16 2024-12-24 스미토모 파마 아메리카, 인크. 염, 결정 형태 및 이들의 제조 방법
JP2022511509A (ja) * 2018-12-06 2022-01-31 サノビオン ファーマシューティカルズ インク 神経障害および神経障害の処置方法
AU2021257786A1 (en) * 2020-04-14 2022-11-03 Sunovion Pharmaceuticals Inc. (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine for treating neurological and psychiatric disorders
IL318169A (en) * 2020-08-26 2025-03-01 Vertex Pharma Apol1 inhibitors and methods of use are the same
AU2022251503B2 (en) * 2021-03-29 2024-11-07 Jiangsu Nhwa Pharmaceutical Co., Ltd Spiro-containing derivative, and preparation method therefor and use thereof
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative
CN115677718B (zh) * 2021-07-30 2024-11-01 武汉思瓴生物科技有限公司 甲基甲胺类衍生物制剂、药物组合物及其应用
AU2022348905A1 (en) 2021-09-23 2024-04-11 Sumitomo Pharma America, Inc. Methods of treating metabolic disorders
CN115677719B (zh) * 2022-10-27 2025-03-07 复旦大学 一种芳基并杂环化合物及其制备方法和用途

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4036842A (en) 1972-05-16 1977-07-19 American Home Products Corporation Process for preparing polycyclic heterocycles having a pyran ring
US4021451A (en) 1972-05-16 1977-05-03 American Home Products Corporation Process for preparing polycyclic heterocycles having a pyran ring
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4021452A (en) 1975-04-23 1977-05-03 American Cyanamid Company 2,5-Dihydro-2,5-dialkoxyfuran derivatives
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4127665A (en) 1978-01-18 1978-11-28 Pfizer Inc. Thienohydantoin derivatives
FR2459239A1 (fr) 1979-06-20 1981-01-09 Logeais Labor Jacques Nouveaux derives amines du benzothiazole, leur procede de preparation et leur application en therapeutique
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
IE67334B1 (en) 1988-03-16 1996-03-20 Smithkline Beecham Farma Heterocyclic derivatives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
DE3827727A1 (de) 1988-08-16 1990-02-22 Boehringer Ingelheim Kg Anellierte tetrahydropyridinessigsaeurederivate, verfahren zu deren herstellung und verwendung solcher verbindungen zur kardioprotektion
GB8824400D0 (en) 1988-10-18 1988-11-23 Glaxo Group Ltd Chemical compounds
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
GB8827479D0 (en) 1988-11-24 1988-12-29 Zambeletti Spa L Novel compounds
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
EP0416740A3 (en) 1989-08-08 1991-08-28 Beecham Group P.L.C. Novel compounds with renin-inhibiting activity
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
GB8927872D0 (en) 1989-12-08 1990-02-14 Beecham Group Plc Pharmaceuticals
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
ZA912744B (en) 1990-03-23 1992-02-26 Zambeletti Spa L Pharmaceuticals
JPH049367A (ja) 1990-04-26 1992-01-14 Zeria Pharmaceut Co Ltd アリールアルカノイル誘導体，該化合物の製造中間体及びそれらを含有する医薬
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9018139D0 (en) 1990-08-17 1990-10-03 Pfizer Ltd Therapeutic agents
NZ240155A (en) 1990-10-29 1992-10-28 Ishihara Sangyo Kaisha Heterocyclyl acyl and (hexahydro) indanyl acyl substituted hydrazine derivatives, preparation thereof and pesticidal compositions
DE4104257A1 (de) 1991-02-13 1992-08-20 Boehringer Ingelheim Kg Verwendung von anellierten tetrahydropyridinessigsaeurederivaten fuer die behandlung neurologischer erkrankungen
GB9104839D0 (en) 1991-03-07 1991-04-17 Zambeletti Spa L Novel compounds
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
PH31294A (en) 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
JP3223277B2 (ja) 1992-04-10 2001-10-29 カシオ計算機株式会社 楽音制御装置
FR2692264B1 (fr) 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
IT1255178B (it) 1992-06-26 1995-10-20 Pierrel Spa N(eter0)-aril-n(etero)-tetralinalchil piperazine aventi attivita' serotoninergica,dopaminergica e adrenergica
ATE169179T1 (de) 1992-12-02 1998-08-15 Ciba Geigy Ag Selektiv-herbizides mittel
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
JP3163068B2 (ja) 1993-12-27 2001-05-08 日本建工株式会社 野縁取付け金具
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2723091B1 (fr) 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
JP2002506072A (ja) 1998-03-12 2002-02-26 ノボ ノルディスク アクティーゼルスカブ プロテインチロシンホスファターゼ（ＰＴＰａｓｅ）のモジュレーター
HUP0102612A2 (hu) 1998-03-12 2001-11-28 Novo Nordisk A/S Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények
WO1999046267A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
HK1043998B (zh) 1998-12-14 2005-03-18 安斯泰来制药有限公司 哌嗪衍生物
AU776276B2 (en) 1999-01-19 2004-09-02 Neurosearch A/S Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases
US6313309B1 (en) 1999-04-05 2001-11-06 Ortho-Mcneil Pharmaceutical, Inc. 4-thionaphthyl—1H—imidazoles which are usefulα22-adrenoceptoR agonists/ antagonists
AU4589800A (en) 1999-05-05 2000-11-21 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors
DE60023923D1 (de) 1999-09-10 2005-12-15 Novo Nordisk As Modulatoren der protein tyrosin phosphatase (ptpases)
EP1214060A2 (en) 1999-09-10 2002-06-19 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
WO2001032610A1 (en) 1999-10-29 2001-05-10 Kaken Pharmaceutical Co., Ltd. Urea derivative, process for producing the same, and medicine containing the urea derivative
AR030537A1 (es) 1999-11-05 2003-08-27 Abbott Lab Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
AU2001277731A1 (en) 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
AU2001286191A1 (en) 2000-09-12 2002-03-26 Sankyo Company, Limited Quinolizine derivatives
WO2002102387A1 (en) 2001-06-18 2002-12-27 H. Lundbeck A/S Treatment of neuropathic pain
US20040180883A1 (en) 2001-07-11 2004-09-16 Jeremy Gilmore Pharmaceutical compounds with serotonin receptor activity
EP1409476B1 (en) 2001-07-11 2004-12-15 Eli Lilly And Company Pharmaceutical compounds with serotonin receptor activity
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
JP2003261566A (ja) 2002-03-11 2003-09-19 Sankyo Co Ltd キノリジンを含有する医薬
TW200306783A (en) 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
MXPA05004033A (es) 2002-10-16 2005-06-08 Isis Innovation Hidroxilasas de asparaginil y moduladores de las mismas.
US20060241130A1 (en) 2003-01-31 2006-10-26 Ehud Keinan Anti-inflammatory compositions and uses thereof
ES2527185T3 (es) 2003-03-07 2015-01-21 Santen Pharmaceutical Co., Ltd Nuevos compuestos que tienen un grupo 4-piridilalquiltio como sustituyente
JP2004269449A (ja) 2003-03-11 2004-09-30 Ishihara Sangyo Kaisha Ltd ベンズアミド誘導体、それらの製造方法及びそれらを含有する有害生物防除剤
US20070154534A1 (en) * 2003-03-12 2007-07-05 Sheitman Brian B Use of secretin in the treatment of schizophrenia
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
EP1611109A4 (en) 2003-03-31 2009-06-24 Taisho Pharmaceutical Co Ltd NOVEL QUINAZOLINE DERIVATIVES AND THEIR THERAPEUTIC USE
JP2005145859A (ja) 2003-11-13 2005-06-09 Nippon Steel Chem Co Ltd 脱水素化方法及び芳香族複素環化合物の製造方法
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2005072412A2 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
DE102004004974A1 (de) 2004-01-31 2005-08-18 Aventis Pharma Deutschland Gmbh Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
KR100553398B1 (ko) 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
SE0401970D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
JP2006117568A (ja) 2004-10-20 2006-05-11 Mitsubishi Pharma Corp チオフェン環を有する新規アミド誘導体及びその医薬としての用途
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
AR052674A1 (es) 2005-02-17 2007-03-28 Wyeth Corp Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
TW200642683A (en) 2005-04-22 2006-12-16 Sankyo Co Heterocyclic compound
KR20080030630A (ko) 2005-06-27 2008-04-04 이 아이 듀폰 디 네모아 앤드 캄파니 전기 전도성 중합체 조성물
WO2007001939A1 (en) 2005-06-27 2007-01-04 Janssen Pharmaceutica N.V. Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities
US20100168102A9 (en) 2005-07-11 2010-07-01 Devgen Nv Amide Derivatives as Kinase Inhibitors
US8846742B2 (en) 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
US20090264470A1 (en) 2006-02-21 2009-10-22 Bennett Teresa A CB1 Antagonists and Inverse Agonists
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2007126041A1 (ja) 2006-04-28 2007-11-08 Eisai R & D Management Co., Ltd. ベンゾイソオキサゾール化合物
WO2008034087A2 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
JP2010505842A (ja) 2006-10-04 2010-02-25 シェーリング コーポレイション トロンビン受容体拮抗薬としての二環式誘導体および三環式誘導体
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2008058342A1 (en) 2006-11-15 2008-05-22 Genetic Technologies Limited Compounds, compositions and methods for controlling invertebrate pests
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
US7598417B2 (en) 2007-04-12 2009-10-06 Allergan, Inc. Substituted fluoroethyl ureas as alpha 2 adrenergic agents
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP1982987A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Spiro-pyrano-pyrazole derivatives
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2009067202A1 (en) 2007-11-21 2009-05-28 Janssen Pharmaceutica, N.V. Spiropiperidines for use as tryptase inhibitors
US7973051B2 (en) 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
EP2230230A4 (en) 2007-12-07 2011-03-16 Nissan Chemical Ind Ltd SUBSTITUTED DIHYDROAZOL COMPOUND AND PESTICIDES
WO2009085256A1 (en) 2007-12-27 2009-07-09 Panacos Pharmaceuticals, Inc. Anti-hiv compounds
CN101759710B (zh) 2008-10-06 2011-10-05 山东轩竹医药科技有限公司 含有取代的氮杂环的头孢菌素衍生物
WO2010053583A2 (en) 2008-11-10 2010-05-14 Dana Farber Cancer Institute Small molecule cd4 mimetics and uses thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
WO2011036889A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
US20120214784A1 (en) 2009-11-16 2012-08-23 Eli Lilly And Company Spiropiperidine compounds as orl-1 receptor antagonists
SG10201401661RA (en) * 2009-12-04 2014-07-30 Sunovion Pharmaceuticals Inc Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders
TWI523851B (zh) 2009-12-28 2016-03-01 Yakult Honsha Kk 1,3,4-oxadiazole-2-carboxamide
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2560636A4 (en) 2010-04-23 2013-11-27 Kineta Inc ANTIVIRAL CONNECTIONS
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012122340A1 (en) 2011-03-10 2012-09-13 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
CN102731574B (zh) 2011-03-30 2016-03-02 中国人民解放军军事医学科学院毒物药物研究所 噻吩并吡啶类α-胺基苄基膦酸酯、其制备方法及用途
WO2013010453A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Chemoking receptor antagonists
WO2016013475A1 (ja) 2014-07-23 2016-01-28 シャープ株式会社 表示装置およびその駆動方法
JP7146782B2 (ja) * 2017-02-16 2022-10-04 サノビオン ファーマシューティカルズ インク 統合失調症を処置する方法
KR102746817B1 (ko) 2018-02-16 2024-12-24 스미토모 파마 아메리카, 인크. 염, 결정 형태 및 이들의 제조 방법
WO2019161236A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Methods of treating social function disorders
JP2022511509A (ja) 2018-12-06 2022-01-31 サノビオン ファーマシューティカルズ インク 神経障害および神経障害の処置方法

Also Published As

Publication number Publication date
JP7146782B2 (ja) 2022-10-04
IL268694B1 (en) 2023-06-01
JP7402945B2 (ja) 2023-12-21
WO2018151861A1 (en) 2018-08-23
CA3053903A1 (en) 2018-08-23
AU2018220509B2 (en) 2022-04-28
WO2018151861A8 (en) 2019-09-06
IL268694A (en) 2019-10-31
EP3582815A1 (en) 2019-12-25
IL268694B2 (en) 2023-10-01
MX2022001778A (es) 2022-03-22
MX2019009763A (es) 2019-11-21
AU2018220509A1 (en) 2019-09-12
CN110678205A (zh) 2020-01-10
US11129807B2 (en) 2021-09-28
IL303177A (en) 2023-07-01
US20250057806A1 (en) 2025-02-20
US20200129477A1 (en) 2020-04-30
WO2018151861A9 (en) 2019-06-13
CN116808023A (zh) 2023-09-29
US20220062229A1 (en) 2022-03-03
AU2022209266A1 (en) 2022-08-25
NZ756367A (en) 2024-12-20
KR20190129035A (ko) 2019-11-19
JP2022191257A (ja) 2022-12-27
MX390141B (es) 2025-03-20
CN110678205B (zh) 2023-05-23
KR102605854B1 (ko) 2023-11-23
JP2020507602A (ja) 2020-03-12

Similar Documents

Publication Publication Date Title
ZA202409975B (en) Methods of treating schizophrenia
EA202090510A1 (ru) Способ лечения бокового амиотрофического склероза придопидином
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
MX373964B (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
EA201200355A1 (ru) Способы предотвращения и лечения ишемии головного мозга
EA201490029A1 (ru) Соединения, ингибирующие металлоферменты
IN2015DN00438A (enExample)
EA201791710A1 (ru) Антитела к транстиретину
EA201991650A1 (ru) Способы лечения неврологических расстройств
EA201791711A1 (ru) Антитела к транстиретину
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
MY178390A (en) Inhibitors of iap
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
NZ773183A (en) Mini-gde for the treatment of glycogen storage disease iii
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EA201690763A1 (ru) Лечение рака поджелудочной железы
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX381311B (es) Método para el tratamiento de prurito y/o comezón.